TN SB0733 | 2023-2024 | 113th General Assembly
Status
Spectrum: Partisan Bill (Republican 1-0)
Status: Introduced on January 30 2023 - 25% progression, died in committee
Action: 2023-03-15 - Action deferred in Senate Health and Welfare Committee to 1/24/2024
Pending: Senate Health and Welfare Committee
Text: Latest bill text (Draft #1) [PDF]
Status: Introduced on January 30 2023 - 25% progression, died in committee
Action: 2023-03-15 - Action deferred in Senate Health and Welfare Committee to 1/24/2024
Pending: Senate Health and Welfare Committee
Text: Latest bill text (Draft #1) [PDF]
Summary
As introduced, prohibits a healthcare provider from prescribing a buprenorphine product unless the patient has first signed a copy of an informational document on the risks of buprenorphine use to pregnant women, unborn children, and infants; requires the department of health to make available on its public website the informational document within 90 days of the effective date of the act. - Amends TCA Title 53 and Title 63.
Title
AN ACT to amend Tennessee Code Annotated, Title 53 and Title 63, relative to buprenorphine.
Sponsors
| Sen. Rusty Crowe [R] |
History
| Date | Chamber | Action |
|---|---|---|
| 2023-03-15 | Senate | Action deferred in Senate Health and Welfare Committee to 1/24/2024 |
| 2023-03-08 | Senate | Placed on Senate Health and Welfare Committee calendar for 3/15/2023 |
| 2023-02-06 | Senate | Passed on Second Consideration, refer to Senate Health and Welfare Committee |
| 2023-02-02 | Senate | Introduced, Passed on First Consideration |
| 2023-01-30 | Senate | Filed for introduction |
Same As/Similar To
HB0665 (Crossfiled) 2023-02-01 - Assigned to s/c Health Subcommittee
